Long-term randomized trial of intensive versus symptomatic management in Paget's disease of bone: The PRISM-EZ study by Tan, Adrian et al.
 1 
 
Long term randomised trial of Intensive versus Symptomatic Management in Paget’s 
Disease of Bone: The PRISM-EZ study 
 
 
Adrian Tan MB ChB 1 
Kirsteen Goodman PhD2 
Allan Walker 2 
Jemma Hudson MSc3 
Graeme S MacLennan, MSc 3 
Peter L Selby MD 4  
William D Fraser, MD 5 
Stuart H Ralston, MD 1,2 
for the PRISM-EZ Trial Group 
 
1 Rheumatology and Bone Disease Unit, University of Edinburgh, UK 
2 Edinburgh Clinical Trials Unit, Edinburgh, UK  
3 Health Services Research Unit, University of Aberdeen, UK 
4 Institute of Human Development, Faculty of Medical and Human Sciences, University of 
Manchester; Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation 
Trust, Manchester Academic Health Science Centre, Manchester M13 9WL. 
5 Department of Medicine, University of East Anglia, UK 
 
Corresponding Author:  
Professor Stuart H Ralston MD 
Centre for Genomic and Experimental Medicine 
Institute of Genetics and Molecular Medicine 
University of Edinburgh  
Western General Hospital 
Edinburgh EH4 2XU, UK 
Phone: +44-131-651-1037 
Fax: +44-131-651-1085  
Email: stuart.ralston@ed.ac.uk 
 
  
 2 
 
Abstract 
It has been suggested that normalization of bone turnover may improve clinical outcome in Paget’s 
disease of bone (PDB) by preventing complications such as fractures and the progression of 
osteoarthritis. Here we investigated the long-term effects of a treatment strategy that aimed to 
normalize bone turnover in PDB with that of symptomatic treatment. The study group comprised 
502 subjects who were enrolled into a three-year extension of the Paget’s Disease: Randomised Trial 
of Intensive versus Symptomatic Management (PRISM) study. Intensive bisphosphonate therapy was 
continued in 270 of these subjects with the aim of normalising serum total alkaline phosphatase 
(ALP) concentrations using zoledronic acid as the treatment of first-choice. Symptomatic treatment 
was continued in 232 subjects where bisphosphonates were given only if there was bone pain 
thought to be caused by PDB. The primary outcome was fracture and secondary outcomes were 
orthopaedic procedures, quality of life and bone pain, adjusted for baseline characteristics. Serum 
total ALP concentrations were significantly lower in the intensive group on entry to the study and 
the differences between groups increased as the study progressed. There were no clinically 
important differences in quality of life measures or bone pain between the treatment groups. 
Intensive treatment was associated with a non-significant increase in fracture risk (hazard ratio 
=1.90, [95% confidence interval 0.91 to 3.98], p=0.087), orthopaedic procedures (1.81 [0.71 to 4.61], 
p=0.214), and serious adverse events (relative risk 1.28 [0.96-1.42].  
We conclude that long-term intensive bisphosphonate therapy confers no clinical benefit over 
symptomatic therapy and is associated with a non-significant increase in the risk of fractures, 
orthopaedic events and serious adverse events.  The results of this study suggest that in patients 
with established PDB, bisphosphonate therapy should focus on control of symptoms rather than 
suppression of bone turnover. 
 
Trial registration 
ICTRN (12989577) 
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Introduction 
Paget’s disease of bone (PDB) is a common skeletal disorder with a strong genetic component that 
affects up to 2% of Caucasians over the age of 55 years(1). It is characterised by increased bone 
resorption, coupled to increased and disorganized bone formation at one or more skeletal sites. 
Many patients with PDB never come to medical attention (2), but bone deformity, pathological 
fracture, deafness and secondary osteoarthritis and bone pain are common in those that do present 
clinically, significantly impairing quality of life (3,4). Bisphosphonates are highly effective at 
suppressing the elevated bone turnover that is characteristic of PDB (5-8)and are an effective 
treatment for bone pain associated with PDB (9). It has been suggested that normalisation of bone 
turnover with bisphosphonates might prevent complications of PDB (10) but this remains unproven 
(11). Nonetheless, the Endocrine Society clinical guidelines recently advised that bisphosphonates 
should be administered to most patients with PDB with the aim of normalising bone turnover in the 
hope this will prevent complications (12).  
The Paget’s Disease Randomised Trial of Intensive versus Symptomatic Management (PRISM) study 
(13) showed that intensive bisphosphonate therapy and symptomatic treatment had similar effects on 
clinical outcome of PDB with respect to the occurrence of fractures, orthopaedic procedures, 
hearing loss, bone pain, quality of life and adverse events. Here we report the results of a three-year 
extension of the PRISM trial (PRISM, extension with zoledronic acid; PRISM-EZ) in which the same 
treatment strategies were continued but where the highly potent bisphosphonate zoledronic acid (14) 
was used as the treatment of first choice in the intensive arm. 
Methods 
Study Design  
The design of the PRISM study has previously been reported (13). In brief, the treatment goal in the 
intensive arm was to supress bone turnover by reducing and maintaining serum total alkaline 
phosphatase (ALP) concentrations within the reference range whereas the treatment goal in the 
symptomatic arm was to treat bone pain thought to be due to PDB with analgesics or with 
bisphosphonates if the response to analgesics was inadequate. Participants who completed the 
PRISM study were invited to take part in a three-year extension in which the same treatment 
strategies were continued but where zoledronic acid was used as the bisphosphonate of first choice 
in the intensive arm. Enrolment into the study commenced in January 2007 and the study ended in 
January 2012. 
Randomisation and study treatment 
Patients were randomised into one of the two treatment groups on entry to PRISM using a 
minimisation algorithm to ensure balance for key prognostic variables as previously described (13). 
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During PRISM-EZ participants were continued on the same treatment strategy as they had been 
randomised to in the PRISM study. Participants in the intensive arm were prescribed 
bisphosphonates as required to supress and maintain ALP concentrations within the normal range. 
Zoledronic acid was the treatment of first choice. Participants in the symptomatic arm received 
treatment with bisphosphonates only if bone pain was present that was considered to be due to 
increased metabolic activity of PDB. Both groups of subjects received analgesics and non-steroidal 
anti-inflammatory drugs as required.  
Outcome measures 
The primary outcome was clinical fracture. Other secondary outcomes included orthopaedic 
procedures, serum total ALP concentrations; bone pain and health related quality of life. Quality of 
life was measured using various tools including the Medical Outcomes Study 36 Item Short-Form 
Health Survey (SF-36) questionnaire(15); the Stanford Health Assessment Questionnaire Disability 
Index (16) (HAQ); the EuroQoL questionnaire, (EQ-5D); and the arthritis specific version of SF36  (ASHI) 
(17). Bone pain was recorded and physicians were asked to assess whether they considered that the 
bone pain was attributable to PDB. The commonest criteria used by physicians for attributing bone 
pain to PDB were; localisation of pain to an affected site; response of pain at that site to previous 
treatment with bisphosphonate; pain at rest and pain at night (13). Information on fractures, 
orthopaedic procedures and serious adverse events were collected on a continuous basis. 
Measurements of ALP, quality of life and bone pain were made annually. Data on adverse events 
were collated annually based on patient diaries. Fractures and orthopaedic procedures were 
validated against medical records by assessors blinded to treatment allocation. Serum total ALP was 
measured according to standard techniques by the biochemistry laboratories at participating 
centres. The measured ALP values were normalised to the upper limit of the local laboratories’ 
reference range to give adjusted ALP values so that results could be compared across centres. The 
adjusted values were categorised into four groups; low-normal (ALP below the 50th centile of the 
local reference range); normal (between the 50th -100th centile of the reference range); high (up to 
three times above the upper limit of the reference range) and very high (more than three times 
above the upper limit of the reference range).  
Statistical Analysis 
We did not perform a power calculation since this was an extension of an existing study. The 
statistics are reported as number and percentages or numbers and mean ± standard deviation (SD) 
as appropriate unless otherwise stated. We used propensity scoring (18) to adjust for differences 
between groups in baseline characteristics include age, gender, age at diagnosis, family history of 
PDB, sites of involvement, deafness, renal function, bone pain, bone deformity, previous fractures, 
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previous orthopaedic surgery for PDB and quality of life measures. The propensity scores were 
derived from the standardised differences between groups shown in supplementary table 1. Unless 
otherwise stated, the analyses performed used inverse probability of treatment weighting (IPTW) in 
logistic regression models with propensity scores as explanatory variables and treatment as the 
independent variable. Flexible parametric models were used for the time-to-event outcomes of 
fracture and orthopaedic procedures (19). Estimates of the effect sizes are presented as hazard ratios 
with 95% confidence intervals. The quality of life data and ALP measurements were analysed using 
linear mixed models with a random effect for participant and centre to reflect the repeated 
measures nature of the data.  All available data at each follow-up time-point was used and no 
adjustment was made for missing data (20). All statistical analyses were IPTW adjusted unless 
otherwise stated.  
Ethics 
All participants gave written informed consent to be included in the study. The trial was approved by 
the UK Multicentre Research Ethics Committee for Scotland (MREC01/0/53); by local ethical review 
boards in the participating study centres and by the Medicines & Healthcare Products Regulatory 
Authority (CTA 21583/0002/001-0001).  The study was included in the controlled clinical trials 
register (www.controlled-trials.com) and assigned the reference number ISRCTN12989577. 
Patient involvement 
The research questions in the PRISM study were developed in consultation with patient 
representatives from the Paget’s Association – a UK based patient support organisation and a 
representative from the Paget’s Association served as a member of the trial steering committee on 
both PRISM and PRISM-EZ. 
Results 
Characteristics of the Study Population 
The disposition of subjects is shown in figure 1. We invited 991 patients who completed the PRISM 
study to take part in the extension study and 502 (50.7%) agreed. The symptomatic group in PRISM-
EZ comprised 232 patients (47.7% of those in the symptomatic arm that completed PRISM) whereas 
the intensive group comprised 270 subjects (53.5% of those in the intensive arm that completed 
PRISM). Relevant baseline characteristics of patients that consented to participate in PRISM-EZ as 
compared with those that did not are shown in supplementary Table 2. The clinical characteristics of 
both groups were similar except that patients who consented to take part in PRISM-EZ were about 4 
years younger than those who did not participate.  In total, 191 subjects in the symptomatic group 
(82.3%) and 213 subjects in the intensive group (78.8%) completed the study, providing 613 patient-
years of follow up in the symptomatic group and 698 patient years of follow up in the intensive 
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group. Relevant demographic and clinical characteristics of the study population at the baseline visit 
of PRISM-EZ are shown in table 1. Prior to entering PRISM-EZ, participants had been followed up for 
an average of 4.3 years since enrolment in PRISM giving a total duration of 7.3 years of treatment 
and follow up. The groups were well matched for most variables at entry to PRISM-EZ with the 
exception of serum total adjusted ALP concentrations which were lower at baseline in the intensive 
treatment group and bisphosphonate use which was more common in the intensive group (Table 1).  
Treatment Received 
There was a significant difference between the two groups in the range and type of bisphosphonates 
given for PDB during the study which was consistent with the study protocol (supplementary Table 
3). Zoledronic acid was given to a higher proportion of patients in the intensive group (28.1% vs 
10.3%, p<0.001) whereas fewer patients in the intensive group received pamidronate (4.8% vs 
15.5%, p<0.001). The proportion of patients who received risedronate and etidronate was similar in 
both treatment groups. Some patients also were receiving bisphosphonate treatment for 
osteoporosis (alendronic acid 70mg weekly, risedronate 35mg weekly; and ibandronate 150mg 
monthly or 3mg intravenously 3 monthly) but there was no significant difference in the proportion 
of patients who received these medications between the groups. Use of analgesics and NSAID in the 
treatment groups are summarised in Table 2. These agents were used by a high proportion of 
patients with no significant differences between the treatment groups. 
Serum Alkaline Phosphatase 
Serum total ALP concentrations during the study are shown in Figure 2. At the baseline visit 75.2% of 
the intensive group had normal or low normal ALP values compared with 63.7% of the symptomatic 
group. At year two, ALP values were normal or low normal in 86.4% of the intensive group compared 
with 64.1% of the symptomatic group and corresponding values at year 3 were 85.3% and 70.3%. 
The difference between groups was statistically significant at all time points (Figure 2). Biochemical 
relapse, defined as the occurrence an elevated ALP during the study in patients where ALP 
concentrations were normal or low normal at baseline occurred in 29 patients (8.5%) of whom 17 
(58.6%) were in the symptomatic group and 12 (41.3%) were in the intensive group.  
Quality of Life and bone pain 
Quality of life summary scores assessed by the SF36 questionnaire are shown in Table 3. There was 
no sustained difference in quality of life measures in favour of one group or the other during the 
study. Changes in physical component summary score (+1.6, p=0.04) and arthritis specific health 
index (+2.6, p<0.001) were observed at year 1 in favour of the intensive treatment group whereas 
changes in the mental component summary score at year three favoured the symptomatic 
treatment group (-2.4, p=0.019). Changes in the Stanford disability index favoured the symptomatic 
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group at year 1 (-0.06, p=0.05). There was no significant difference in EQ5D scores between 
treatment groups (data not shown). Changes in the SF36 subscales are shown in Supplementary 
table S4. Differences in physical function (+1.7, p=0.04) and bodily pain (+2.8, p<0.001) were 
observed which favoured the intensive group at one year but not at other time points. The 
magnitude of change in SF36 scores were in all cases less than the five point threshold which is 
considered clinically significant (15). The proportion of patients with bone pain was not different 
between groups during the study, but for bone pain rated by the physician as being due to PDB there 
was a marginal benefit at year two in favour of the intensive group (+1.3, p=0.009).  
Fractures and orthopaedic procedures 
Fractures and orthopaedic procedures that occurred during the study are summarised in Table 4. 
There was a non-significant excess of patient with fractures in the intensive group 22 vs. 12 
(adjusted hazard ratio 1.90, 95% confidence intervals 0.91-3.98, p=0.087). The same was true of 
orthopaedic procedures (15 vs. 7, adjusted hazard ratio 1.81 [0.71-4.61], p=0.214). Most fractures 
occurred in unaffected bone and might have been due to osteoporosis, but a similar trend was 
observed for fractures and orthopaedic procedures in bone that was affected by PDB.  No fractures 
were observed that met the ASBMR criteria for atypical femoral fractures (21). However, 6 of the 7 
fractures (85%) that occurred in Pagetic bone affected the subtrochanteric or diaphyseal region of 
deformed femurs. One of these occurred in a patient in the intensive group at the site of a pre-
existing stress fracture and was preceded by the occurrence of local pain. Twelve patients in the 
intensive group (4.4%) had previously suffered a fracture during PRISM as compared with 22 in 
PRISM-EZ (8.1%). By comparison, 13 patients (5.6%) in the symptomatic group suffered a fracture 
during PRISM as compared with 12 in PRISM-EZ (5.2%). Only one patient who suffered a fracture 
during PRISM also fractured in PRISM-EZ but different bones were affected. There was no significant 
association between low ALP values and the occurrence of fractures; of the 34 patients who suffered 
a fracture during PRISM-EZ, 17 (50%) were recorded as having a low ALP value, compared with 
247/468 patients (52.7%) with a low ALP that did not suffer a fracture (p=0.85, Fishers exact test). 
Fractures and orthopaedic procedures when combined, were significantly more common in the 
intensive group (adjusted hazard ratio 1.92 95% CI 1.04-3.53, p = 0.036) although caution should 
be exercised in the interpretation of this result since it was not a pre-specified analysis in 
the study protocol. 
Exposure to bisphosphonates and skeletal events 
Since both treatment groups received bisphosphonates during the study we conducted an 
exploratory analysis to evaluate possible associations between bisphosphonate use during PRISM-EZ 
and skeletal events. The results for fracture are shown in supplementary Table 5 and for orthopaedic 
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procedures in supplementary Table 6. This showed that fractures were more common in patients 
that received bisphosphonates in the intensive group (12.7% vs. 3.1%, p=0.0036), the symptomatic 
group (12.7% vs. 0%, p<0.0001) and both groups combined (14.1% vs.1.5%, p<0.0001). There was no 
association between treatment with individual bisphosphonates and fracture. There was no 
significant excess of orthopaedic procedures in patients that received bisphosphonates as compared 
with those that did not, in the intensive group (4.0% vs. 7.6%, p=0.285), the symptomatic group 
(5.1% vs. 1.5%, p=0.076) or both groups combined (4.4% vs. 4.4%, p=1.00). 
Adverse Events 
Adverse events reported during the study are summarised in Table 5. There was a non-significant 
excess of serious adverse events in the intensive group occurring (32.2% vs 28.4%, relative risk 1.28, 
95% CI 0.96-1.42]. However the proportion of patients with non-serious adverse events was almost 
identical in both groups (relative risk 0.99, 95% CI [0.92-1.08]. Some rare adverse events that have 
previously been associated with bisphosphonates were numerically more common in the intensive 
group including osteonecrosis of the jaw (1 vs. 0) uveitis (1 vs. 0) arrhythmias (14 vs. 5) and delayed 
fracture healing (2 vs. 1)  
Discussion 
The aim of the PRISM-EZ study was to determine whether long term suppression of bone turnover 
with intensive bisphosphonate therapy conferred any clinical advantage over symptomatic 
treatment in patients with established PDB.  On entry to PRISM-EZ, participants had already been 
treated with intensive or symptomatic therapy for an average of 4.3 years, which when added to 
treatment given during PRISM-EZ, provided a total duration of treatment and follow up of 7.3 years. 
As expected, serum ALP concentrations were significantly lower in the intensive group at baseline 
and the differences between groups increased as the study progressed. However, we observed no 
consistent differences in patient reported outcomes such as quality of life, bodily pain or bone pain 
between the two treatment groups. There were statistically significant differences at year one in 
bodily pain, physical component summary score and arthritis specific health index favouring the 
intensive group but the effect size was small and below the five point threshold that is considered 
clinically significant. Bone pain rated by the physician as being due to PDB was less common at year 
two in the intensive group but the magnitude of effect was small and differences were not observed 
at other time-points. The pain data are consistent with the findings of Reid and colleagues who 
reported that zoledronic acid treatment improved SF36 bodily pain score by a margin of about two 
points when compared with risedronate (6). Taken together, these observations suggest that 
zoledronic acid may have a slightly greater effect on pain and quality of life than less potent 
bisphosphonates. In the PRISM-EZ study however, the effects of intensive bisphosphonate therapy 
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on pain and quality of life were transient and below the threshold that is considered clinically 
significant. In keeping with this, there was no clear association between suppression of bone 
turnover and symptom control, emphasised by the fact that SF36 bodily pain scores were similar in 
subgroups of patients with low ALP, normal ALP and high ALP throughout the study. 
There was a non-significant increase in the risk of fractures, orthopaedic procedures and serious 
adverse events with intensive therapy. We also found that in both treatment groups, patients who 
suffered fractures were more likely to have received bisphosphonates than those who had not 
suffered fractures.  Since the number of events was small it is difficult to draw firm conclusions but 
the data raise the possibility that prolonged suppression of bone turnover in PDB might increase the 
risk of fracture.  In this regard, over-suppression of bone turnover has been associated with an 
increased risk of atypical fractures in both osteoporosis (22,23) and PDB (24).  
Like all trials, the PRISM-EZ study has weaknesses. The number of fractures and orthopaedic 
procedures was small and although there was an excess of both events in the intensive group, this 
could have been a chance finding. It is also important to emphasise that participants in PRISM-EZ 
were a selected group since only about one half of the subjects who completed PRISM went onto 
take part in PRISM-EZ. Nonetheless the clinical characteristics of patients who participated in PRISM-
EZ were similar to those that did not apart from the fact that they were about 4 years younger. 
Finally, the study focused on patients with established PDB most of whom had previously been 
treated with bisphosphonates and already had developed complications such as bone pain, fractures 
and deformity. It is therefore importance to emphasise that the lack of benefit of intensive 
bisphosphonate treatment on clinical outcome may not apply to previously untreated patients with 
early PDB. The PRISM-EZ study has several strengths however. It is the largest and longest running 
clinical trial ever to be conducted in PDB and is the only trial that has examined the effects of 
treatment on fractures and orthopaedic procedures. Since the participants that entered PRISM-EZ 
were typical of those being treated in secondary care in the UK, it’s likely that the results are 
generalizable to patients with established PDB who have already been treated with 
bisphosphonates. The results reported here do not support the recommendations made by the 
Endocrine Society guideline group (12) which suggested that most patients with PDB should be 
treated with potent bisphosphonates with the aim of restoring ALP values to within the lower part of 
the reference range. On the contrary, the PRISM-EZ study demonstrates that this strategy is not 
associated with clinical benefit and might be harmful. Rather the present data suggest that a more 
appropriate indication for bisphosphonate treatment in PDB is to control bone pain thought to be 
due to disease activity.  
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Table 1. Baseline characteristics of the study population  
 Intensive 
(n=270) 
Symptomatic 
 (n=232) 
Male 149 (55.2) 125 (53.9) 
Age at entry to PRISM-EZ (years) 75.6±8.1 76.0±8.2 
Years since enrolment in PRISM 4.3±0.8 4.3±0.8 
Age at diagnosis of PDB (years) 63.4±10.2 63.8±10.4 
Family history 45 (16.7) 43 (18.5) 
Number of affected bones   
   One 
   Two 
   Three 
   Four or more 
Affected sites 
97 (35.9) 
78 (28.8) 
54 (20.0) 
41 (15.1) 
95 (37.1) 
67 (28.8) 
41 (17.6) 
29 (12.5) 
   Skull 66 (24.4) 62 (26.7) 
   Spine 104 (38.5) 82 (35.3) 
   Pelvis 181 (67.0) 142 (61.2) 
   Femur 98 (36.3) 71 (30.6) 
   Tibia 53 (19.6) 42 (18.1) 
   Other 96 (35.6) 78 (33.6) 
Deafness 46 (17.0) 38 (16.4) 
Serum adjusted ALP¶ 0.9±0.7 1.1±1.0* 
Low ALP 96 (35.6) 77 (33.2) 
Normal ALP 100 (37.0) 64 (27.6) 
High ALP 62 (23.0) 73 (31.5) 
Very high ALP 3 (1.1) 8 (3.4) 
Serum creatinine (µmol/L) 92.0±24.9 94.6±30.1 
Bone pain‡ 166 (61.5) 149 (64.2) 
Bone pain due to PDB† 68 (25.2) 72 (31.0) 
SF36 Physical Component Summary 37.5 ± 11.5 38.3 ± 11.6 
SF36 Bodily pain 41.5 ± 11.4 41.9 ± 11.7 
SF36 Mental Component Summary 47.3 ± 11.8 48.9 ± 12.3 
Bone deformity 134 (49.6) 108 (46.6) 
Previous fractures 121 (44.8) 103 (44.4) 
Fracture in Pagetic bone 31 (11.5) 27 (11.6) 
Orthopaedic surgery for PDB 70 (25.9) 48 (20.7) 
Previous bisphosphonate therapy 214 (79.3) 138 (59.5)*** 
Bisphosphonate use in PRISM 202 (74.8) 123 (53.0)*** 
Bisphosphonates administered in PRISM   
   Alendronate 4 (1.5) 5 (2.2) 
   Risedronate 154 (57.0) 41 (17.7) 
   Etidronate 6 (2.2) 10 (4.3) 
   Tiludronate 8 (3.0) 50 (21.6) 
   Pamidronate 64 (23.7) 51 (22.0) 
   Clodronate 3 (1.1) 1 (0.4) 
   Zoledronic acid 5 (1.9) 3 (1.3) 
 
Values are mean ± standard deviation or n (%). ‡ Patient reported bone pain; † Bone pain considered 
by the clinician to be due to Paget’s disease; * p = 0.02, *** p<0.0001 between groups; ¶a value of 
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1.0 is equivalent to the upper limit of the reference range. Data were available for ALP in 261 of the 
intensive and 222 of the symptomatic group; for SF36 summary scores in 208 of the intensive and 
180 of the symptomatic group; and for SF36 bodily pain in 216 of the intensive and 188 or the 
symptomatic group. 
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Table 2. Analgesic use during study 
  
Intensive 
(n=270) 
Symptomatic 
(n=232) 
Relative risk 
[95% CI] 
Any analgesic 200 (74.1) 182 (78.4) 0.94 [0.85-1.04] 
Paracetamol 122 (45.2) 120 (51.7) 0.87 [0.72-1.05] 
Compound analgesics 87 (32.2) 64 (27.6) 1.18 [0.89-1.57] 
Dihydrocodeine or tramadol 33 (12.2) 33 (14.2) 0.92 [0.58-0.48] 
Anti-neuropathic drugs 3 (1.1) 5 (2.2) 0.40 [0.09-1.72] 
Opioids 12 (4.4) 11 (4.7) 0.89 [0.39-2.05] 
NSAID 70 (25.9) 64 (27.6) 0.97 [0.72-1.30] 
 
Values are numbers (%) 
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Table 3. Effect of treatment on quality of life summary scores and bone pain 
 Time Intensive 
(n=270) 
Symptomatic 
(n=232) 
Standardised mean 
difference 
[95% CI] 
p-value 
Physical component summary Year 1 185, 37.5±0.9 153, 37.0±0.9 1.6 [0.1, 3.1] 0.04  
Year 2 136, 36.1±1.0 120, 36.9±1.1 0.8 [-1.5, 3.2] 0.49  
Year 3 172, 36.4±0.9 160, 35.6±0.9 0.9 [-1.1, 2.9] 0.39 
Arthritis Specific health index Year 1 185, 37.6 ±1.0 153, 36.4 ±1.0 2.7 [1.3,4.0] <0.001  
Year 2 136, 35.7±1.2 120, 36.6±1.2 0.7 [-1.6,2.9] 0.57  
Year 3 172, 36.6± 1.0 160, 36.1± 1.0 0.8 [-1.4. 3.1] 0.46 
Mental component summary Year 1 185, 46.9±0.9 153, 47.6±1.0 0.6, [-1.2, 2.4] 0.54  
Year 2 136, 46.6±1.0 120, 48.2±1.0 -0.2, [-2.2, 1.9] 0.88  
Year 3 172, 46.7±0.9 160, 49.0±1.0 -2.4 [-4.3,-0.4] 0.02 
Standard disability index Year 1 185, 0.92±0.06 153,1.02±0.6 -0.06 [-0.13,0.00] 0.05 
 Year 2 136, 1.05±0.07 120, 1.03±0.6 -0.03 [-0.17,0.12] 0.71 
 Year 3 172 1.09±0.07 160, 1.15 ±0.7 0.04 [-0.10,0.19] 0.56 
Alternative disability index Year 1 185, 0.72±0.06 153, 0.76±0.06 0.00 [-0.06,0.07] 0.99 
 Year 2 136, 0.84±0.07 120, 0.80±0.07 -0.03 [-0.15,0.08] 0.57 
 Year 3 172 0.86±0.06 160, 0.87±0.06 0.04 (-0.09,0.17] 0.57 
Bone Pain‡ Year 1 148 (54.8) 115 (49.6) 0.52 [-0.5, 1.5] 0.29  
Year 2 123 (45.6) 104 (44.8) 0.02 -0.6, 0.7] 0.94  
Year 3 130 (48.1) 112 (48.3) 0.68 [-0.1, 1.5] 0.09 
Bone pain due to PDB† Year 1 44 (16.3) 40 (17.2) -0.57 [-1.7, 0.6] 0.34 
 Year 2 40 (14.8) 36 (15.5) 1.30 [0.3, 2.3] 0.009 
 Year 3 34 (12.6) 37 (15.9) -0.71 [-2.0, 0.5] 0.26 
 
Values are number of observations, mean ± sem or numbers (%). Positive scores for standardised mean difference favour 
the intensive group and negative scores the symptomatic group. Comparison between groups is adjusted using IPTW. (%). ‡ 
Patient reported bone pain; † Bone pain considered by the clinician to be due to Paget’s disease 
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Table 4. Effect of treatment on Fractures and Orthopaedic Procedures 
 Intensive 
(n=270) 
Symptomatic 
(n=232) 
Hazard ratio 
[95% CI] 
p-value 
Patients with fracture 22 (8.1) 12 (5.2) 1.90 [0.91-3.98] 0.087 
Number of fractures 24 12   
Fractures in Pagetic bone 5 2   
Patients requiring orthopaedic surgery 15 (5.6) 7 (3.0) 1.81 [0.71-4.61] 0.214 
Number of procedures 16 9   
Procedures in Pagetic bone 7 4   
   Joint replacements 11 4   
   Osteotomy 2 2   
   Other procedures 1 3   
Patients with fracture or orthopaedic surgery 34 (12.6) 17 (7.3) 1.92 [1.045-3.53] 0.036 
Patients with fracture and orthopaedic surgery 3 3   
Number of fractures and orthopaedic 
procedures 
40 22   
 
Values are numbers (%). Comparison between groups is adjusted using IPTW. The hazard ratio and p-values are for time to 
first event. 
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Table 5. Adverse events reported during study 
 Intensive 
(n=270) 
Symptomatic 
(n=232) 
Relative risk 
[95% CI] 
Serious Adverse Events 87 (32.2) 66 (28.4) 1.28 [0.96-1.72] 
Total Number of Adverse 
Events 
226 (83.7) 196 (84.5) 0.99 [0.92-1.08] 
   Cardiovascular 67 (24.8) 49 (21.1) 1.080 [0.76-1.52] 
   Cerebrovascular 4 (1.5) 3 (1.3) 1.027 [0.20-5.18] 
   CNS 28 (10.4) 28 (12.1) 0.918 [0.54-1.56] 
   Endocrine 28 (10.4) 21 (9.1) 1.628 [0.92-2.87] 
   ENT 28 (10.4) 26 (11.2) 1.020 [0.59-1.75] 
   Gastrointestinal 54 (20.0) 46 (19.8) 1.014 [0.69-1.48] 
   Genitourinary 41 (15.2) 39 (16.8) 1.024 [0.67-1.57] 
   Haematological 10 (3.7) 9 (3.9) 1.081 [0.43-2.71] 
   Musculoskeletal 123 (45.6) 104 (44.8) 1.063 [0.86-1.31] 
   Miscellaneous 33 (12.2) 32 (13.8) 0.993 [0.61-1.62] 
   Respiratory 48 (17.8) 43 (18.5) 0.911 [0.61-1.35] 
   Ophthalmic 34 (12.6) 41 (17.7) 0.685 [0.44-1.07] 
   Skin 41 (15.2) 33 (14.2) 1.108 [0.70-1.74] 
Values are number (%) of people with at least one event. ENT - ear, nose or throat; 
CNS -Central nervous system. 
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Figure 1. Disposition of Study subjects 
 
Disposition of the patients from the start of PRISM to the end of PRISM-EZ is shown. Withdrawn 
indicates that the patient was withdrawn by the clinician; declined indicates that the patient 
declined further follow up. Lost indicates that the patient was lost to follow up 
Assigned to treatment in 
PRISM (n=1324)
Completed PRISM 
(n=486)
Symptomatic 
(n=270)
Intensive  
(n=232)
Completed PRISM
(n=505)
Declined (n=214) Declined (n=233)
Active 12 months 
(n=253)
Deceased (n=7)
Withdrawn (n=2)
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Lost (n=2) 
Active 12 months 
(n=220)
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Withdrawn (n=2)
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Lost (n=1) 
Active 24 months 
(n=232)
Deceased (n=17)
Withdrawn (n=4)
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Lost (n=4) 
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(n=202)
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Lost (n=4) 
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(n=213)
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Withdrawn (n=7)
Declined (n=21)
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Figure 2. Serum alkaline phosphatase concentrations 
 
Changes in adjusted alkaline phosphatase during the study are shown in panel a. The symbols are 
means and vertical bars standard error of the mean. The reference range is indicated by the shaded 
area. * p=0.02 between groups; *** p<0.001 between groups. Panels b, c and d show the proportion 
of patients with serum alkaline phosphatase values in each category at years 1-3. The differences 
were significant at all time points (see text). Low normal: at or below the 50th centile of the normal 
range; Normal: between the 50th centile and the upper limit of normal; High: up to three times 
normal; very high: more than three times normal.  
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